Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 12Neoplasm Metastasis 6Glioblastoma 4Triple Negative Breast Neoplasms 3Brain Neoplasms 3Pancreatic Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Hereditary Sensory and Autonomic Neuropathies 2Carcinoma, Non-Small-Cell Lung 2Treatment for Metastatic or Locally Advanced Cervical Cancer 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Pre-menopausal Breast Cancer 1Non-Small Cell Lunch Cancer 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Locally Advanced Solid Tumor 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Gliosarcoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Rituximab 101Cyclophosphamide 51Prednisone 32Doxorubicin 32Vincristine 31Gemcitabine 29Lenalidomide 27Oxaliplatin 22Bendamustine Hydrochloride 19ibrutinib 16fludarabine 16tafasitamab 12polatuzumab vedotin 12venetoclax 11tisagenlecleucel 11obinutuzumab 11loncastuximab tesirine 9Etoposide 9zanubrutinib 8Prednisolone 8Injections 8Ifosfamide 8Carboplatin 8selinexor 7pembrolizumab 7durvalumab 7axicabtagene ciloleucel 7Dexamethasone 7tazemetostat 6parsaclisib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, Large B-Cell, Diffuse × NVP-BKM120 × Clear all
NCT01693614 2018-09-28

Safety and Efficacy of BKM120 in Relapsed and Refractory NHL

Novartis

Phase 2 Completed
72 enrolled 15 charts
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡